兩種HPV檢測方法在宮頸癌篩查中準(zhǔn)確性比較的Meta分析
發(fā)布時間:2018-09-06 20:25
【摘要】:目的:評價HPV E6/E7 mRNA(Aptima)和HPV DNA二代雜交捕獲(HC2)檢測對宮頸上皮內(nèi)瘤變2級(CIN2)及以上病變(≥CIN2)的診斷價值。方法:檢索Cochrane圖書館、Pubmed、Embase、中國知網(wǎng)和萬方數(shù)據(jù)庫,收集Aptima和HC2用于宮頸癌篩查的研究數(shù)據(jù)。通過meta分析合并診斷效應(yīng)量,比較Aptima和HC2對≥CIN2的診斷效能。結(jié)果:共納入13篇文獻,初篩人群累計31523例(其中Aptima 15767例,HC2 15756例)。轉(zhuǎn)診人群累計13982例(其中Aptima 7004例,HC2 6978例)。初篩人群中,Aptima和HC2診斷≥CIN2的匯總敏感度分別為0.95(95%CI為0.91~0.98)和0.95(95%CI為0.90~0.97),匯總特異度分別為0.90(95%CI為0.90~0.98)和0.85(95%CI為0.84~0.86)。轉(zhuǎn)診人群中,Aptima和HC2診斷≥CIN2的匯總敏感度分別為0.93(95%CI為0.92~0.94)和0.95(95%CI為0.93~0.96),匯總特異度分別為0.47(95%CI為0.45~0.48)和0.38(95%CI為0.36~0.39)。初篩人群中,Aptima和HC2診斷≥CIN2的AUC分別是0.9672和0.8888,Q*統(tǒng)計量分別為0.9154和0.8194;轉(zhuǎn)診人群中,Aptima和HC2診斷≥CIN2的AUC分別是0.8389和0.8766,Q*統(tǒng)計量分別為0.7708和0.8070,差異均無統(tǒng)計學(xué)意義。結(jié)論:Aptima與HC2對≥CIN2病變的診斷敏感度和診斷效能相當(dāng),但Aptima的特異度相對更高。
[Abstract]:Objective: to evaluate the diagnostic value of HPV E6/E7 mRNA (Aptima) and HPV DNA second generation hybridization capture (HC2) in the diagnosis of cervical intraepithelial neoplasia grade 2 (CIN2) and above lesions (鈮,
本文編號:2227441
[Abstract]:Objective: to evaluate the diagnostic value of HPV E6/E7 mRNA (Aptima) and HPV DNA second generation hybridization capture (HC2) in the diagnosis of cervical intraepithelial neoplasia grade 2 (CIN2) and above lesions (鈮,
本文編號:2227441
本文鏈接:http://sikaile.net/yixuelunwen/fuchankeerkelunwen/2227441.html
最近更新
教材專著